Using an I125-TGF-β binding and crosslinking assay, we found that ALK4 loss led to increased surface expression of TβRI and TβRII in breast and pancreatic cancer cells (Fig. 5a, b, Supplementary Fig. 11a, b). Here, TGFBR2 is linked to pancreatic neoplasm.